

Contents lists available at ScienceDirect

Blood Reviews

journal homepage: www.elsevier.com/locate/blre

REVIEW

Old and new oral anticoagulants: Food, herbal medicines and drug interactions

Alessandro Di Minno^a, Beatrice Frigerio^a, Gaia Spadarella^b, Alessio Ravani^a, Daniela Sansaro^a, Mauro Amato^a, Joseph P. Kitzmiller^c, Mauro Pepi^a, Elena Tremoli^{a,d}, Damiano Baldassarre^{a,d,*}

^a Centro Cardiologico Monzino, IRCCS, Milan, Italy

^b Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli "Federico II", Naples, Italy

^c College of Medicine, The Ohio State University, Columbus, OH, USA

^d Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy

ARTICLE INFO

Available online xxxx

Keywords:

Warfarin

Direct anticoagulant drugs

Loss of efficacy

Toxicity

Thrombotic/bleeding events

Therapeutic context

Patients characteristics

Co-morbidities

ABSTRACT

The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists (VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important because deviations from their narrow therapeutic window can result in bleedings due to over-anticoagulation or thrombosis because of under-anticoagulation. In addition to pharmacodynamic interactions (e.g., augmented bleeding risk for concomitant use of NSAIDs), interactions with drugs, foods, herbs, and over-the-counter medications may affect the risk/benefit ratio of VKAs. Direct oral anticoagulants (DOACs) including Factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and thrombin inhibitor (dabigatran) are poised to replace warfarin. Phase-3 studies and real-world evaluations have established that the safety profile of DOACs is superior to those of VKAs. However, some pharmacokinetic and pharmacodynamic interactions are expected. Herein we present a critical review of VKAs and DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Until recently, the vitamin K antagonists (VKAs) were the only oral anticoagulant agents available, and warfarin remains the most commonly prescribed oral anticoagulant worldwide. Its indications include a wide range of clinical conditions from prevention of cardioembolic ischemic stroke to deep venous thrombosis and pulmonary embolism. Anticoagulants are used in patients with a history of atrial fibrillation or flutter, recent major surgery or immobility, heart valve replacement, ischemic stroke or other thrombotic event [1]. Warfarin has significant variability in dose-response across individuals and a narrow therapeutic window (the international normalized ratio [PT-INR] value must remain between 2.0 and 3.0 for most indications) [2]. Clinical outcomes are highly correlated with the amount of time patient's PT-INR values are maintained in range [3]. Patients with an average individual time in therapeutic range >70% are considered to be at a low risk of a major hemorrhagic or thrombotic event

[4]. Frequent monitoring of PT-INR lab values and dose adjustments, therefore, are necessary for safe and efficacious use of warfarin [5]. Likewise, patient instruction and identification of factors leading to over- or under-anticoagulation are critical [6,7]. When combined with low-dose aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) or clopidogrel, warfarin acts cumulatively, and risk of bleeding is significantly increased [8,9]. VKAs are among the medications with the highest incidence of drug-related life-threatening events [1] and top the list of interactions with foods, herbal supplements, prescribed drugs and over-the-counter medications [10,11]. Interactions resulting in over- or under-anticoagulation drastically increase the risk of major hemorrhagic or thrombotic event.

Direct oral anticoagulants (DOACs), approved for the prevention and treatment of venous thromboembolism and of systemic and cerebral embolism in atrial fibrillation [12], are poised to replace warfarin for stroke prevention [13]. As their anticoagulant effect is more predictable and stable (i.e., less influenced by interactions with foods, herbal supplements, prescribed drugs and over-the-counter medications), DOACs should prove safer and less problematic compared to the VKAs [14]. Clinical studies of venous and arterial thromboprophylaxis suggest that routine laboratory monitoring is not necessary with thrombin inhibitors or Factor Xa inhibitors. However, potential pharmacodynamic interactions and drug interactions with foods, herbal supplements, prescribed drugs and over-the-counter medications must still be considered with the use of DOACs [15].

* Corresponding author at: Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Via Balzaretti 9, 20133 Milan, Italy.

E-mail addresses: alessandro.diminno@ccfm.it (A. Di Minno), beatrice.frigerio@ccfm.it (B. Frigerio), spadarellagaia@hotmail.it (G. Spadarella), alessio.ravani@ccfm.it (A. Ravani), daniela.sansaro@ccfm.it (D. Sansaro), mauro.amato@ccfm.it (M. Amato), joseph.kitzmiller@osumc.edu (J.P. Kitzmiller), mauro.pepi@ccfm.it (M. Pepi), elena.tremoli@ccfm.it (E. Tremoli), damiano.baldassarre@unimi.it (D. Baldassarre).

2. Vitamin K antagonists (VKAs)

The pharmacokinetic and pharmacodynamic effects on VKAs that result from interactions with foods, herbal supplements, prescribed drugs and over-the-counter medications are summarized in Table 1, and detailed in the Online Appendix. A variety of drugs, herbal medicines, nutrients that may affect dietary intake of Vitamin K may interact with VKAs possibly changing their effect [16]. Mechanisms of such interactions are herein discussed.

2.1. Drug-drug interactions affecting pharmacokinetic of warfarin

Several prescriptions and over-the-counter medications, foods and herbal supplements alter the pharmacokinetics (absorption, distribution, metabolism and elimination) and pharmacodynamics (anticoagulant effect) of warfarin (Table 1) [17,18].

The absorption of warfarin is reduced by concomitant use of cholestyramine and sucralfate [19]. As warfarin is highly bound to plasma proteins, other substances or medications that compete for protein-binding sites (e.g., ibuprofen, quinidine, fenofibrate, losartan, valsartan, amlodipine, felodipine, sulfinpyrazone, phenylbutazone and the principal metabolite of chloral hydrate, i.e. trichloroacetic acid) displace warfarin, potentiating the anticoagulant action of VKAs [20]. This effect, often observed as marginally increased PT-INR, is typically transient and has a delayed onset ranging from 1 day to 3 weeks (in the case of phenprocoumon) after starting the concomitant drug regimen [21,22].

The majority of drug interactions affecting warfarin involves inhibition of the expression and/or activity of CYP450 enzymes involved in warfarin metabolism (CYP2C9 for the *S*-enantiomer and CYPs 1A2, 2C19, 3A4 for *R*-enantiomer of warfarin). Interactions involving the *S*-enantiomer may be of greater impact because the activity (anticoagulant effect) of the *S*-enantiomer is 2 to 5-fold greater than that of the

R-enantiomer [23]. The concomitant use of medications that induce CYP2C9 (e.g., rifampin and phenobarbital) results in increased clearance of warfarin and thus less anticoagulation [24].

Nearly 1 in 3 patients prescribed warfarin also prescribed a statin. Several statins are metabolized by CYP3A4 and CYP2C9 isoenzymes. Altered warfarin metabolism leading to increase PT-INR values has been reported with concomitant use of fluvastatin, lovastatin, simvastatin or atorvastatin [25,26]. As the metabolism of pravastatin and rosuvastatin does not involve CYP450 enzymes, potential for drug-drug interactions with warfarin is limited [27,28]. Other cardiovascular pharmacotherapies that interact with warfarin are listed in Table 2.

HIV-positive patients often require anticoagulation therapy because they are at increased risk of venous thromboembolism or cardiovascular disease [29]. As several of the anti-retroviral agents (e.g., nevirapine, efavirez, saquinavir and ritonavir) used to treat HIV interact with warfarin metabolism by inhibiting/inducing CYP enzymes (Table 3), clinicians treating HIV-positive patients should be informed about the increased likelihood of adverse reactions or decreased efficacy of warfarin therapy in this patient population [30,31,32,33].

Some of the anti-fungal drugs (e.g., fluconazole, miconazole), and antibiotics (e.g., azithromycin, ciprofloxacin) inhibit specific CYP450 iso-enzymes (Table 3), altering warfarin pharmacokinetics and increase PT-INR values and risk of hemorrhage when combined with warfarin [22,34]. In addition, they can also diminish gut absorption of Vitamin K by altering the gut flora. Although this is rarely of clinical significance (other than in malnourished patient populations), this altered ability to absorb vitamin K can result in lowered synthesis of vitamin K-dependent coagulation proteins and, ultimately, in an increased risk of hemorrhage [35].

Several over-the-counter medications significantly alter warfarin metabolism. Increased PT-INR and pro-hemorrhagic effects (e.g. ecchymosis, subcutaneous hematomas, hematuria) have been reported after 2 weeks of concomitant use of over-the-counter anti-fungal “Miconazole (oral gel)”, a strong CYP2C9 inhibitor, used for the treatment of oral Candidiasis [36]. Two case reports of decreased PT-INR values with concomitant use of over-the-counter menthol drops (antitussives) provide another example of potential interactions between warfarin and over-the-counter medications [37,38].

Drug-drug interactions may also affect warfarin elimination. For example, the concomitant use of miconazole and phenylbutazone results in increased warfarin elimination and decrease efficacy of warfarin therapy, by inhibiting the elimination of the *S*-enantiomer [16].

Table 1
Effect of commonly employed drugs on PT-INR [18,28].

Drugs that increase PT-INR	Drugs that lower PT-INR
Drugs active on the central nervous system	
Citalopram ^a	Barbiturates ^a
Disulfiram	Carbamazepine ^a
Entacapone ^a	Chlordiazepoxide
Phenytoin	Propofol
Fluoxetine	Ethanol
Propoxyphene	
Fluvoxamine	
Anti-inflammatory drugs	
Acetaminophen	Azathioprine
Allopurinol	Mesalazine
Celecoxib	Sulfasalazine
Dextropropoxyphene	
Indomethacin	
Interferon	
Methyl-prednisolone	
Phenylbutazone	
Piroxicam ^a	
Sulindac	
Sulfinpyrazone	
Tramadol	
Other	
Cimetidine ^a	Chelating agents
Omeprazole	Cyclosporine
Orlistat	Etretinate
CMF	Anti-flu vaccine
Danazol	Menthol (anti-cough)
5-fluorouracil	Mercaptopurine
Ifosfamide	Methimazole
Levamisole	Multivitamin supplies
Levonorgestrel	Raloxifene
Tamoxifen	
Zileuton ^a	

^a Clinically relevant interactions with warfarin.

Table 2
Cardiovascular drugs interfering with the metabolism/clearance of warfarin [28].

Drug [Reference(s)]	Mechanism(s)
Drugs that increase PT-INR	
Acetyl-salicylic acid	Pharmacodynamics
Amiodarone ^a [24]	Moderate inhibitor of CYP3A4, CYP1A2, CYP2C9
Dronedarone ^a [168,171]	Moderate inhibitor of CYP3A4, inhibitor of P-gp
Atorvastatin [172]	Inhibitor of CYP3A4
Quinidine [173]	Inhibitor of CYP3A4
Clofibrate ^a [174]	Inhibitor of CYP3A4
Diltiazem ^a [28]	Inhibitor of CYP3A4
Disopyramide [175]	Inhibitor of CYP3A4
Fenofibrate ^a [172]	Inhibitor of CYP3A4
Glucagon [176]	Inhibitor of CYP3A4
Lovastatin [172]	Inhibitor of CYP3A4
Propafenone ^a [177]	Inhibitor of CYP3A4
Propranolol ^a [178]	Inhibitor of CYP1A2
Rosuvastatin [179]	Inhibitor of CYP3A4
Simvastatin [25]	Inhibitor of CYP3A4
Drugs that lower PT-INR	
Cholestyramine [28]	Interference with warfarin absorption
Telmisartan [180]	Inhibitor of CYP3A4

^a Clinically relevant interactions with warfarin.

Table 3

Anti-infective drugs interfering with the metabolism/clearance of warfarin [28,181].

Drug [Reference(s)]	Mechanism(s)
Amoxicillin, clavulanic acid [102,103]	Reduced intrinsic vitamin K biosynthesis.
Azithromycin [182]	Moderate inhibitor of CYP3A4, P-gp
Chloramphenicol [183]	Inhibitor of CYP450
Ciprofloxacin [184]	Strong inhibitor of CYP1A2
Clarithromycin [28]	Moderate inhibitor of CYP3A4, P-gp
Sulfamethoxazole [185]	Inhibitor of CYP3A4
Doxycycline [186]	Inhibitor of CYP3A4
Efavirez [32]	Moderate inhibitor of CYP2C19 and of CYP3A4
Erythromycin [187]	Moderate inhibitor of CYP3A4, P-gp
Fluconazole [188]	Moderate inhibitor of CYP3A4, CYP1A2, CYP2C9
Isoniazid [24]	Inhibitor of CYP2C9
Itraconazole [28]	Strong inhibitor of CYP3A4 e P-gp
Ketoconazole [28]	Strong inhibitor of CYP3A4 e P-gp
Levofloxacin [189]	Inhibitor of CYP1A2
Metronidazole [190]	Inhibitor of CYP1A2, CYP2C9
Miconazole gel [191]	Inhibitor of CYP1A2, CYP2C9
Miconazole vaginal suppositories [192]	Inhibitor of CYP1A2, CYP2C9
Nalidixic acid [24]	Inhibitor of CYP1A2
Norfloxacin [185]	Inhibitor of CYP3A4
Ritonavir [193]	Strong inhibitor of CYP3A4, P-gp
Saquinavir [194]	Inhibitor of CYP3A4
Tetracycline [24]	Inhibitor of CYP3A4
Voriconazole [195]	Strong inhibitor of CYP3A4, CYP1A2, CYP2C9, P-gp
Griseofulvin [196]	Inducer of warfarin-metabolizing enzymes
Ritonavir [193]	Strong inducer of CYP2C19
Nafcillin [197]	Strong inducer of CYP3A4
Nevirapine [33; 193]	Strong inducer of CYP3A4
Rifampicin [24]	Inducer of CYP3A4, CYP2C9

In bold, clinically relevant warfarin-drug interactions.

2.2. Drug-drug interactions affecting pharmacodynamic of warfarin

Guidelines [1,4] recommend avoiding routine concomitant use of warfarin and antiplatelet agents, with the exception of appropriate therapeutic regimens in certain well identified clinical conditions [19, 39]. Medications affecting platelet function have a synergistic pharmacodynamic interaction with warfarin; concomitant use, therefore, can result in significant increases in PT-INR and, in turn, in an increased risk of bleeding [40,41,42].

Acetaminophen, a widely used over-the-counter analgesic and antipyretic does not alter platelet function [43], but concomitant use of acetaminophen at doses ≥ 2 g/d for several days increases the pharmacodynamic effect (increased PT-INR) of warfarin. Pharmacodynamic drug interactions with warfarin are often of more clinical relevance than those affecting only the pharmacokinetic of warfarin. Oral contraceptives increase the risk of thrombosis by 4-5 folds compared to placebo [44], and their use in patients prescribed warfarin must be carefully assessed as they decrease protein S and increase the synthesis of vitamin K dependent clotting factors [45].

3. Foods and herbal medicines interactions with warfarin

3.1. Pharmacokinetic interactions of warfarin with food and herbal medicines

Nearly 15% of the US population uses complementary and alternative medicines (CAMs) in parallel with conventional treatments [46]. Detailed clinical information regarding various herbal supplements and medicines and their interactions with warfarin are summarized in Table 4. Unfortunately, most patients receiving warfarin have poor knowledge about the potential interactions of some CAMs and warfarin and seldom inform their clinicians about their concomitant use of CAMs [47].

Table 4

Pharmacokinetic interaction of natural substances/foods with warfarin [20].

Natural substance	Presence of inhibitor(s) of
<i>Citrus bergamia</i>	CYP2C9
Carum Ajowan	CYP3A4
<i>Citrus aurantium</i> (Orange)	CYP3A4
<i>Uncaria</i> (Una de gato)	CYP3A4
<i>Vaccinium Myrtillus</i>	CYP2C9
Devil's clam	CYP2C9
Dehydroepiandrosterone	CYP3A4
<i>Echinacea</i> (purpurea and/or angustifolia)	CYP3A4
<i>Eucalyptus globulus</i>	CYP1A2, 2C9, 2C19, 3A4
<i>Tanacetum parthenium</i>	CYP1A2, 2C9, 2C19, 3A4
Fo-ti-root	CYP1A2, 2C9, 2C19, 3A4
Garlic	CYP2C9, 2C19, 3A4
<i>Hydrastis canadensis</i>	CYP3A4
Grape juice	CYP1A2, 3A4
Ipriflavone	CYP1A2, 2C9
Kava (<i>Piper methysticum</i>)	CYP1A2, 2C9, 2C19, 3A4
Licorice	CYP3A4
Lime	CYP3A4
Wolfberries	CYP2C9
<i>Silybum marianum</i>	CYP2C9, 3A4
Peppermint	CYP1A2, 2C9, 2C19, 3A4
<i>Trifolium pratense</i>	CYP1A2, 2C9, 2C19, 3A4
Resveratrol	CYP1A2, 3A4
Sulforaphane	CYP1A2
<i>Valeriana officinalis</i>	CYP3A4
<i>Prunus avium</i> (wild cherry)	CYP3A4
Natural substance	Presence of inducer(s) of
3,3'-Diindolylmethane	CYP1A2
Ginseng	CYP1A2, 2C9, 2C19, 3A4
Guggul	CYP3A4
Grapes (<i>Vitis vinifera</i>)	CYP1A2
Indole-3-carbinol	CYP1A2
Limonene	CYP2C9
<i>Hypericum perforatum</i>	CYP1A2, 2C9, 3A4

One study of patients prescribed warfarin for chronic atrial fibrillation found that about 50% were also taking an herbal supplement or medication. Warfarin patients taking no herbal medications or only 1 herbal <4 times per week were more likely to have PT-INR values within the optimal therapeutic range (2.0 to 3.0) compared to those taking > 1 type of herbal ≥ 4 times per week (58.1% vs 51.1%, $P = 0.046$) [48]. Findings from several in vitro studies have shown that components of herbal supplements may inhibit CYP2C9. This is seldom of clinical significance because these CYP2C9 components rarely achieve appreciable intrahepatic concentrations [49]. In addition, no data have been reported to date suggesting that foods or nutrients (other than those containing Vitamin K) interact significantly with warfarin CYP2C9 metabolism [50,51].

The most important advice for patients is to maintain their usual diet, since warfarin interactions with food have generally not clinical implications when patients follow a stable diet [52]. Old recommendations for diets low in vitamin K should be considered obsolete [52].

3.1.1. Grapefruit

Components of grapefruit and grapefruit juice, mainly the furanocoumarins, inhibit CYP3A4 activity [53,54]. However, only a few cases of elevated PT-INR and/or minor hematomas have been reported [55]. Nonetheless, clinicians and patients should be aware of the potential interaction between warfarin and grapefruit [54].

3.1.2. Green tea

Although green tea has several reported health benefits [28], high doses markedly reduce PT-INR. A change in PT-INR value from 3.8 to 1.4 has been reported, suggesting the potential for a significant interaction between green tea and VKAs when green tea is consumed in high doses [48]. Moderate consumption of green tea, however, is not likely to affect anticoagulant therapy because green tea contains minimal

amount of Vitamin K [56,57] and the amounts of other compounds that alter CYP activity, such as catechin and flavonoids, are often insufficient to have an appreciable effect on PT-INR [58].

3.1.3. Chamomile (*Matricaria chamomilla*)

Chamomile, an herbal treatment for gastric discomfort, anxiety and catarrh [59], in vitro inhibits CYP1A2 and, to a lesser extent, 3A4 and 2C9 [60]. A case of serious bleeding was observed in a 70-year old female patient on warfarin therapy who consumed large quantities of chamomile [61].

3.1.4. Soybean or soy milk

Soybeans can be used to treat symptoms of menopause, osteoporosis and hyperlipidemia [62]. Although in vitro soybean extracts inhibit CYP3A4 and CYP2C9, they may also impair the anticoagulant activity of warfarin [63,64] because they contain significant amounts of Vitamin K [65].

3.1.5. Mango

Mango contains high concentrations of retinol, a known inhibitor of CYP2C19 [66]. Increases in PT-INR resulting from consuming even small amounts of mango while receiving warfarin therapy can be clinically relevant, and patients and clinicians need be aware of this potential interaction [66,67].

3.1.6. Ginseng

Ginseng does not affect the pharmacokinetics or pharmacodynamics of warfarin [68].

3.1.7. St. John's wort (*Hypericum perforatum*)

St. John's wort, often used to treat moderate depression, sleep disorders, anxiety and pain [69,70], induces CYP1A2 [71], 2C9 [72,73] and 3A4 [74], resulting in increased clearance and reduction of plasma concentrations of warfarin. Long-term consumption of St. John's wort increases the clearance of both the S (+29%, via CYP2C9) and the R (+23%, via CYP3A4/CYP1A2) enantiomers of warfarin, resulting in a clinically significant reduction of the pharmacological effect of warfarin [54,68].

3.1.8. Ginkgo biloba

Consumption of Ginkgo can increase the risk of bleeding in surgical patients. Although one study was unable to detect a difference in warfarin anticoagulation due to concomitant use of Ginkgo, in vitro studies have shown that several flavonol aglycones (e.g., amentoflavone) found in Ginkgo are potent inhibitors of human CYP2C9 [75,76].

3.1.9. Cranberry (*Vaccinium myrtillus*)

Case-reports document increased PT-INR and incidence of hemorrhage attributed to the co-administration of cranberry juice (often used in urinary infections) in patients on warfarin [77,78,79]. Cranberry juice contains marginal amounts of Vitamin K [80,81] and flavonoids' oil. Although in vitro [82], animal [83] and small clinical studies [84, 85,86] suggest that cranberry juice alters CYP2C9 and 3A4 activity, moderate daily consumption of cranberry juice (240–280 mL/d) has little impact on PT-INR.

3.2. Pharmacodynamic interactions of foods and herbal supplements and medicines with warfarin

Green, leafy vegetables and certain vegetable oils contain significant amounts Vitamin K, and their consumption in excess may result in decreased PT-INR. Conversely, decreased consumption or absorption (secondary to changes in gut flora secondary to antibiotic use) of Vitamin K and increased elimination (secondary to diarrhea) of Vitamin K may result in drastic increases in PT-INR and over anticoagulation [28].

Likewise, biliary obstruction and malabsorption have also been associated with decreased levels of Vitamin K and over-anticoagulation [22].

3.2.1. Ginkgo biloba

Ginkgolides, the major chemical components of *Ginkgo biloba*, have anti-inflammatory and anti-platelet properties [87]. In a patient with chronically stable PT-INR values on warfarin, intracranial hemorrhage was reported after 2 months of concomitant use of *Ginkgo biloba* [88]. However, findings from two separate clinical trials reported that standardized extract of Ginkgo (240 mg/d/1 week or 100 mg/d/4 weeks) does not alter the pharmacodynamic of warfarin [89]. Nevertheless, routine monitoring of PT-INR is recommended for patients taking ginkgo in addition to warfarin [54].

3.2.2. Ginseng

Ginsenosides, the major active components of ginseng, inhibit CYP1A2 [87], platelet aggregation and thromboxane formation [90,91]. The findings from three separate reports suggest that ginseng marginally increases the anticoagulant effect of warfarin [90,92,93].

4. Interactions affecting pharmacokinetic or pharmacodynamics of phenprocoumon and acenocoumarol

In patients on chronic phenprocoumon, the increased risk of bleeding of patients co-medicated with verapamil [59] and the increased risk of thrombosis of patients co-medicated with carbamazepine [94] suggest changes in phenprocoumon bioavailability as well as specific effects on CYP450 enzymes playing a major role in the metabolism of this VKA. Interactions between phenprocoumon and ambrisentan [95], esomeprazole [96] and metformin [97] were also reported. In addition, interactions with older macrolide antibiotics erythromycin and clarithromycin, which inhibit CYP3A4, can trigger life-threatening hemorrhage and contribute to the incidence of medical drug-related hospitalizations [98]. Likewise, inhibition of CYP3A4-catalyzed metabolism of phenprocoumon by clarithromycin may result in an increase of both bioavailability and risk of bleeding [99]. Avoidance of concomitant use of co-trimoxazole with phenprocoumon (or acenocoumarol) is a safer approach for the prevention of these potential interactions [100].

4.1. Phenprocoumon

A significantly elevated risk of major bleeding has been observed for drugs with known pharmacodynamic interactions with phenprocoumon [101]. For instance, an increased risk of bleeding was reported with the combined use of phenprocoumon and clopidogrel [101].

Antibiotics associated with an increased risk of hemorrhage in phenprocoumon users include quinolones with ORs ranging from 2.74 (95% CI: 1.80–4.18) for ciprofloxacin to 4.40 (95% CI: 2.45–7.89) for levofloxacin, to 2.99 (95% CI: 1.39–6.42) for amoxicillin plus clavulanic acid and to 3.57 (95% CI: 2.36–5.40) for cotrimoxazole [102,103]. Among NSAIDs, ketoprofen and naproxen were associated with the highest risks [101]. Selective serotonin reuptake inhibitors (SSRIs), such as citalopram, which inhibits the transport of serotonin into the platelets, lead to impaired platelet function thus increasing the risk of bleeding [104,105].

4.2. Acenocoumarol

CYP2C9 polymorphisms have an impact on drug-drug interactions during acenocoumarol treatment [106]. Case-reports and case-series document interactions between acenocoumarol and levofloxacin [107], topical terbinafine [108], amorolfine [109] or ciclopirox [110]. Increased PT-INR after acenocoumarol co-administration with gefitinib [111] or with capcitabine [112] have also been reported. Phenytoin and acenocoumarol share the same metabolizing pathway by hepatic CYP2C9. The co-administration of therapeutic doses markedly

decreases the metabolism of both drugs, leading to acute phenytoin toxicity and increased PT-INR, especially in individuals homozygous for CYP2C9*3 [113].

Special emphasis has been devoted to oral anticoagulation in HIV patients. Interaction between antiretroviral drugs (efavirenz and atazanavir/ritonavir) with acenocoumarol has been documented together with the possibility of a safe concurrent use (i.e. the lack of interaction) of acenocoumarol with raltegravir [114]. Pulmonary arterial hypertension is an uncommon although life-threatening complication of HIV infection, which is treated with bosentan and oral anticoagulants. However, because of its ability to induce the acenocoumarol metabolism and, in turn, to increase PT-INR values, bosentan co-administration with acenocoumarol (and other VKAs) requires a closer PT-INR monitoring not only during the first weeks of treatment, but also during longer periods [115]. Sitaxentan is a conventional therapy for pulmonary hypertension with/without HIV positivity. Sitaxentan inhibits the metabolism of acenocoumarol, resulting in a need for adjustment of acenocoumarol dose when the two drugs are co-administered. In a subset of patients enrolled in the STRIDE-3 study, a PT-INR ≥ 5 in at least one determination was observed in 13 patients on long-term co-treatment with acenocoumarol, although no a clinically significant bleeding event was recorded [116].

A potentiation of acenocoumarol-induced anticoagulation by co-medication with omeprazole or esomeprazole and inhibition of CYP2C19 were also reported [117]. The risk for over-anticoagulation was most pronounced for esomeprazole (HR 1.99, 95% CI 1.55–2.55) and lansoprazole (HR 1.49, 95% CI 1.05–2.10), whereas a non-significant risk increase for the other proton-pump inhibitors (PPIs) was observed [117]. In the same report, no modification of these findings was reported because of different CYP2C19*2 genotypes. Laryngeal hematoma in relation to interaction between acenocoumarol and topical econazole lotion has also been reported because of drug-drug interaction affecting acenocoumarol elimination [118]. Finally, in addition to red Ginseng (used for tiredness and dizziness), reduction of anticoagulant therapy efficacy (low PT-INR) with need to increase the dosage of acenocoumarol was reported for a series of herbal medicines used for weight loss [119].

A 15% decrease in acenocoumarol clearance ($P < 0.05$) when 1 g of amoxicillin + 250 mg of clavulanic acid were co-administered has been reported in healthy volunteers [120]. In contrast, co-administration of sulfamethoxazole-trimethoprim with acenocoumarol increased by 3-fold the risk of over-anticoagulation. Clopidogrel and

acetylsalicylate are also relevant to increase the risk of bleeding [121], while oral contraceptives and hormone replacement therapy tend to offsetting the effect of acenocoumarol [121].

5. Direct oral anticoagulant drugs (DOACs)

Comparative pharmacokinetics and pharmacodynamics of DOACs vs warfarin are summarized in Online Table S1 and detailed in the Online Appendix of this report.

5.1. Dabigatran

5.1.1. Drug-drug interactions affecting the pharmacokinetic of dabigatran

Pharmacokinetic interactions of DOACs with drugs are reported in Table 5; relevant pharmacological interactions with dabigatran and their clinical relevance are summarized in Table 6 and those with Factor Xa inhibitors in Table 7.

Dabigatran etexilate, being not metabolized by cytochrome P450, has low potential for clinically relevant interactions with drugs metabolized by cytochrome P450 [122]. By contrast, this drug is a substrate for P-glycoprotein 1 (P-gp) [123] and its co-administration with strong P-gp inhibitors (e.g. ketoconazole and verapamil) or P-gp inducers (e.g. rifampicin, St. John's wort, carbamazepine and phenytoin) should be avoided [124]. No dose adjustment is needed with the concomitant use of P-gp inhibitor amiodarone, whereas the usual dose 150 mg BID should be reduced to 110 mg BID in patients receiving verapamil [125]. Dronedarone should not be co-administered with dabigatran because it increases the levels of the later drug up to 2-fold [126]. Overall, dabigatran etexilate should be given at least 2 h prior to co-administering any P-gp inhibitor [127].

Atorvastatin (CYP3A4 substrate), diclofenac (CYP2C9 substrate) or digoxin (P-gp inhibitor) have limited impact on dabigatran efficacy, safety and tolerability [128]. Dabigatran absorption is reduced by co-administration of anti-acids such as PPIs [129], even if this effect is seldom of clinical relevance. Dabigatran bioavailability increases after co-administration of ketoconazole [130] or quinidine [131] and decreases after co-administration of rifampicin [132]. Hence, these co-administrations should be avoided.

5.1.2. Drug-drug interactions affecting the pharmacodynamic of dabigatran

The co-administration of dabigatran with other anticoagulant/antiplatelet drugs should be avoided and/or limited in time, unless

Table 5
Pharmacokinetic interactions of DOACs with drugs.

Drug	Inhibitor of	Direction of the change in plasma concentrations in response to coadministration of drugs reported in the first column			
		Dabigatran [28]	Rivaroxaban [28,136]	Apixaban [28,136]	Edoxaban [149]
Cyclosporine	P-gp				
Digoxin	P-gp	↑			
Amiodarone	P-gp	↑			↑
Dronedarone	P-gp	↑			↑
Verapamil	P-gp	↑			↑
Quinidine	P-gp	↑			↑
Ritonavir	P-gp and CYP3A4	↑	↑	↑	↑
Ketoconazole	P-gp and CYP3A4	↑	↑		↑
Itraconazole	P-gp and CYP3A4	↑	↑		↑
Voriconazole	P-gp and CYP3A4	↑	↑	↑	
Posaconazole	P-gp and CYP3A4		↑	↑	
Azithromycin	P-gp and CYP450				↑
Erythromycin	P-gp and CYP450	↑			↑
Clarithromycin	P-gp and CYP450	↑			↑
Drug	Inducer of				
Rifampicin	P-gp and CYP3A4	↓	↓	↓	
Phenytoin	P-gp and CYP3A4	↓	↓	↓	
Carbamazepine	P-gp and CYP3A4	↓	↓	↓	
Fenobarbital	P-gp and CYP3A4		↓	↓	

↑ = increase in concentration; ↓ = reduction in concentration.

Table 6
Clinical use of dabigatran: relevant pharmacological interactions.

Drugs to be avoided	Drugs to be used with caution	Drugs of free use	Drugs that enhance the effect	Drugs that impair the effect
Carbamazepine ^d	Quinidine ^c	Amiodarone ^c	Amiodarone	Proton pump inhibitors
Cyclosporine ^c	Quinine	Atorvastatin (CYP3A4)	Dronedarone ^c	
Dronedarone ^c	Verapamil ^c	Clarithromycin ^{a,c}	Ketoconazole ^a	
Ketoconazole ^c		Diclofenac (CYP2C9)	Quinidine	
Phenytoin ^d		Digoxin (P-gp)	Quinine	
Rifampicin ^d			Verapamil ^c	
St. John's wort ^d				
Verapamil ^c				

^a Inhibitors of Cytochrome P450 iso-enzyme (CYP3A4).^b Inducers of Cytochrome P450 iso-enzyme (CYP3A4).^c Inhibitors of P-glycoprotein (P-gp).^d Inducers of P-glycoprotein (P-gp).

specifically defined. Co-administration with clopidogrel increases the AUC and the C_{max} of dabigatran of 30 and 40%, respectively [28]. In addition, co-administration of dabigatran with aspirin (or diclofenac) requires caution, because of the high risk of bleeding [19].

5.2. Rivaroxaban

5.2.1. Drug-drug interactions affecting the pharmacokinetic of rivaroxaban

Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin leads to $\approx 50\%$ decrease in mean AUC of Rivaroxaban [125]. Thus, decreases in rivaroxaban plasma concentrations are expected in patients concomitantly treated with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St. John's wort). Hence, caution is mandatory for such co-administrations.

By affecting its intestinal excretion, P-gp increases rivaroxaban plasma concentrations [133]. Active substances, however, which strongly inhibit only one of the elimination pathways, e.g. CYP3A4 or P-gp, increase rivaroxaban concentrations only at a limited extent. For instance, co-administration of the strong CYP3A4 inhibitor and moderate P-gp inhibitor clarithromycin (or erythromycin) leads to small and clinically irrelevant increases in mean rivaroxaban AUC and C_{max} [133]. In contrast, co-administration of rivaroxaban with the strong CYP3A4 and P-gp inhibitors ketoconazole or ritonavir leads to a 2.6- and 2.5-fold increase in mean rivaroxaban AUC and a 1.7- and 1.6-fold increase in mean rivaroxaban C_{max} , respectively, which translates into a higher than

normal risk of bleeding [134,135]. Thus, concomitant treatment with strong inhibitors of both CYP3A4 and P-gp is contraindicated.

5.2.2. Drug-drug interactions affecting the pharmacodynamic of rivaroxaban

No significant pharmacodynamic effects were reported when aspirin [136] or clopidogrel [137] were co-administered with rivaroxaban. In a study, however, clopidogrel does significantly prolong (≈ 3 -fold) the mean bleeding time of subjects treated with Rivaroxaban [138]. Similarly, co-administration of 15 mg rivaroxaban with 500 mg naproxen for two consecutive days was associated with a non-clinically significant prolongation of the bleeding time [139]. Finally, because of its additive effect, co-administration of rivaroxaban with other anti-coagulant drugs (e.g. the anti Xa enoxaparin) is discouraged [28, 140].

5.3. Apixaban

5.3.1. Drug-drug interactions affecting the pharmacokinetic of apixaban

The concomitant use of apixaban with strong CYP3A4 and P-gp inducers (e.g. phenytoin, carbamazepine, phenobarbital, rifampicin, or St. John's wort) may lead to reduced apixaban plasma concentrations; hence caution is mandatory when apixaban is co-administered with strong CYP3A4 and P-gp inducers [141].

Table 7
Clinical use of rivaroxaban, apixaban and edoxaban: relevant pharmacological interactions.

Drugs to be avoided	Drugs to be used with caution	Drugs of free use	Drugs that enhance the effect	Drugs that impair the effect
Amiodarone ^c	Carbamazepine ^b	Atorvastatin	Azithromycin	Carbamazepine
Chloramphenicol ^a	Hypericum	Clarithromycin	Clarithromycin	Hypericum
Clarithromycin ^{a,c}	perforatum ^{d,b}	Digoxin	Cyclosporine	Perforatum
Cyclosporine ^c	Phenytoin ^{d,b}	Erythromycin	Diltiazem	Phenobarbital
Dronedarone ^c	Rifampicin ^d	Fluconazole	Dronedarone ^c	Phenytoin
Itraconazole ^a		Midazolam	Erythromycin	Rifampicin
Ketoconazole ^a			Itraconazole	
Quinidine ^c			Ketoconazole	Co-administration of apixaban with rifampicin causes a significant decrease in mean AUC and C_{max} of apixaban.
Quinine			Naproxen	
Ritonavir ^a			Quinidine	
Verapamil ^c			Ritonavir	
			Systemic Antifungals	
			Verapamil	
Concomitant treatment with edoxaban is also contraindicated in subjects receiving erythromycin and azithromycin.			The dose of edoxaban should be halved when the drug is co-administered with dronedarone, quinidine, or verapamil. No dose adjustment is required for amiodarone.	

^a Inhibitors of Cytochrome P450 iso-enzyme (CYP3A4).^b Inducers of Cytochrome P450 iso-enzyme (CYP3A4).^c Inhibitors of P-glycoprotein (P-gp).^d Inducers of P-glycoprotein (P-gp).

Apixaban is not recommended also in patients receiving concomitant treatment with strong CYP3A4 or P-gp inhibitors, such as Ketocazole and ritonavir, which may increase dramatically its plasma concentrations [142,143,144]. Diltiazem and other moderate CYP3A4 inhibitors as well as weak P-gp inhibitors lead to small increases in mean apixaban AUC and C_{max} and, in turn, to little effects on apixaban pharmacokinetics. Naproxen an inhibitor of P-gp but not of CYP3A4, leads to a 1.5- and 1.6-fold increase in mean apixaban AUC and C_{max} , respectively [145]. No dose adjustment is needed when apixaban is co-administered with weak inhibitors of CYP3A4 and/or P-gp.

5.3.2. Drug-drug interactions affecting the pharmacodynamic of apixaban

In healthy volunteers or in patients with atrial fibrillation [146], but not in those with acute coronary syndromes [147], apixaban can be safely combined with aspirin or clopidogrel. In contrast, co-administration of naproxen and apixaban leads to an increased bioavailability of this DOAC [148]. As for rivaroxaban, also the co-administration of apixaban with low-molecular weight heparins is discouraged.

5.4. Edoxaban

5.4.1. Drug-drug interactions affecting the pharmacokinetic of edoxaban

Concomitant treatment with edoxaban is contraindicated in subjects receiving ritonavir, cyclosporine, erythromycin, azithromycin, clarithromycin, ketoconazole, itraconazole because these drugs increase its steady-state plasma concentrations [149]. Edoxaban metabolism is also largely affected by P-gp inhibitors or inducers. Edoxaban dose should be halved when co-administered with P-gp inhibitors that increase edoxaban exposure ≥ 1.5 -fold (dronedarone: 84.5%; quinidine: 76.7%; verapamil: 52.7%) [150,151], whereas no dose adjustment is needed when edoxaban is co-administered with amiodarone that increases edoxaban exposure by only 40% [152].

5.4.2. Drug-drug interactions affecting the pharmacodynamic of edoxaban

In line with other DOACs, also edoxaban has major pharmacodynamic interactions with antibiotics (clarithromycin, erythromycin, rifampicin), anticoagulants (enoxaparin, warfarin), NSAIDs (ketoprofen, naproxen) and platelet inhibitors (naproxen, clopidogrel, aspirin) [153,154,155]. Pharmacodynamic interactions of edoxaban with low-dose (100 mg) or high-dose (325 mg) of aspirin, or naproxen (500 mg) administered to healthy subjects, seems not to be clinically relevant [155]. In fact, although concomitant administration of edoxaban with high-dose aspirin, low-dose aspirin, or naproxen increases template bleeding times (BT) of approximately 2-fold, the effects of edoxaban on PT-INR, anti-FXa, and intrinsic FXa activity were not influenced by either aspirin or naproxen. Moreover, inhibition of platelet aggregation by high-dose aspirin, low-dose aspirin, or naproxen is not affected by edoxaban [155].

6. Foods and herbal medicines interactions with pharmacokinetic or pharmacodynamics of DOACs

No direct evidence is available regarding the inherent risk of co-administration of food or herbal medicines with DOACs. St. John's wort, a potent inducer of P-gp and CYP3A4, is expected to lower plasma concentrations of dabigatran (substrate of P-gp) and of rivaroxaban or apixaban (substrates of P-gp and CYP3A4). Such co-administration should be made with caution with dabigatran and avoided with rivaroxaban or Apixaban [124]. Although, in theory, food or herbal inhibitors/inducers of CYP3A4 might interfere with the pharmacokinetics of DOACs, no direct evidence of such interactions exists. Some food and herbal medicines modulate P-gp in vitro (Table 8) [156] but no information is available whether these substances interact with DOACs. Finally, to the best of our knowledge, no information is available concerning pharmacodynamic interactions of DOACs with foods or herbal medicines.

Table 8

Foods and herbal drugs that modulate P-gp activity [156].

	Inhibitors [Reference(s)]	Inducers [Reference(s)]
Humans	<i>Ginkgo biloba</i> [198] Berberine [199]	St. John's wort [199]
Animal models	Black pepper [200] Grape juice [201] Apigenin [202] Rutin [202] Capsaicin [205]	Quercetin [199] <i>Scutellaria</i> [199] Soy milk and miso [203] Sucralose [204] Licorice root [199]
In vitro	Lemonin [206] Soybean extract [208] Notoginsenoside R1 [210] Curcumin [211] Green tea [212] Fisetin [213] Honokiol [213]	Genipin [207] Mango [209]

7. Food, herbal medicines and drug interactions with oral anticoagulants: clinical relevance and conclusions

7.1. Warfarin

Due to its complex multi-step metabolism, the large majority of warfarin interactions are mediated by CYP2C9, 1A2, 2C19 and 3A4 isoenzymes. Inhibitors and inducers of these enzymes do affect the pharmacological activity of warfarin and, in turn PT-INR values. In most cases adverse drug reactions due to these interactions lead to bleeding events that may be severe, life-threatening and even fatal.

There is no convincing evidence to indicate that any food or nutrient (other than Vitamin K) interacts significantly with warfarin through modulation of CYP2C9 activity [50,51].

Herbal medicines that inhibit CYP2C9 in vitro would not be clinically important unless the inhibitor reaches the liver in sufficient concentrations to inhibit the enzyme in vivo. The discrepancy between in vitro [75] and in vivo [76] effects of the potent inhibitors of human CYP2C9 flavonol aglycones clearly elucidates this concept.

Drug interactions involving CYP2C9, CYP1A2 and CYP3A4 isozymes are usually delayed. The effect of the interaction will not be observed until the interacting agent has reached a steady state (about 5 half-lives of the interacting agent) [157]. Additionally, given the indirect mechanism of the effect of warfarin, clotting factors present in the circulation should be depleted prior to detecting the effect of the interacting agent. This will take several days. Together, the onset and the offset of the interaction (i.e. the effect on the PT-INR) is observed within 3 to 5 days for interacting substances with short half-lives and at longer time intervals for drugs with longer half-lives. All in all, depending on the interacting agent employed, the full impact of steady-state interactions may not be apparent for 2 to 3 weeks. Likewise, a wash-out period of several weeks may be needed before normalization of the hepatic enzymes, when the inducer is discontinued.

Genetic polymorphisms of the CYP2C9 and of the Vitamin K epoxide reductase complex subunit 1 (VKORC1, see Online Appendix) enzymes have a strong impact on drug interactions and, in turn, the responsiveness of warfarin [158]. Individuals with polymorphisms that reduce the expression of functional CYP2C9 will appear to be "warfarin sensitive," in that usual warfarin doses cause excessive anticoagulation [159]. The 2C9*3 variant (Ile359Leu) shows an 80% loss of enzymatic activity in vitro, whereas the CYP2C9*2 variant (Arg144Cys) reduces the activity by $\approx 30\%$. Under these conditions, decreased clearance and increased in vivo anticoagulant effect have been shown [160]. The inter-individual variation due to the CYP2C9 genotype appears to be comparable to that related to a major non-genetic factor e.g. patient age [161].

Age, body weight, body surface area, sex, antibiotics that alter the intestinal environment, disease conditions and dietary intake of Vitamin K affect the responsiveness to warfarin as much as genetic polymorphisms [162,163]. In patients with significant medical illness requiring

multiple medications and having a poor nutritional status, the ability to isolate the impact of a particular medication on the patient's coagulation status is difficult. Broad-spectrum antibiotics are postulated to potentiate warfarin by altering the normal intestinal flora, thereby reducing the body's ability to synthesize Vitamin K. However, this factor is unlikely to be clinically significant for most patients, except those who are malnourished or have malabsorption [164]. In addition to albumin, warfarin is highly bound to a variety of plasma proteins and has the potential for interacting with other highly protein-bound substances. However, the effect of such interactions is usually transient and its clinical significance questionable [22].

Pharmacodynamic drug interactions with warfarin are more clinically relevant than those with foods and drugs. Any medication that impairs the ability of platelets to function (e.g., acetylsalicylic acid, clopidogrel, NSAIDs) and is given concomitantly with warfarin may increase the risk of bleeding without affecting the PT-INR. Aspirin and NSAIDs behave like this [41]. Conversely, medications such as estrogens increase the risk of thrombosis and their use in patients who are taking warfarin should be carefully assessed [44].

7.2. DOACs

Large-scale phase 3 studies [14], and real-world evaluations have definitely established that the use of DOACs is well tolerated (as compared to warfarin), and that adverse reactions (including intra-cerebral bleeding) are quantitatively and qualitatively less relevant than those with warfarin from a clinical standpoint [165,166]. Thus, the use of DOACs is likely to grow as more data become available regarding their long-term use and their use in specific patients' populations.

Pharmacokinetics of Factor Xa inhibitors may be affected by the co-administration of inducers/inhibitors of CYP3A4 and/or P-gp [133,167,168]. In particular, potent inhibitors of CYP3A4 and of P-gp (e.g. ketocozazole - antifungal drug - or protease inhibitors of HIV) should be avoided [169]. Caution is also suggested for the co-administration of potent inducers of CYP3A4 and of P-gp (e.g. carbamazepine, phenytoin) [170].

Being able to affect circulating levels of the anticoagulant drug, strong inhibitors/inducers of P-gp should not be co-administered with dabigatran, a specific substrate for P-gp.

Little information is so far available as to the interaction of DOACs with food, most herbal medicines or over-the-counter medications. Since some herbal drugs and over-the-counter medications modulate P-gp activity (Table 8), their ability to affect the anticoagulant potential of DOACs should be thoroughly analyzed. However, while ad hoc phase IV studies are needed in this area, a limited clinical impact of such herbal drugs and over-the-counter medications to affect DOACs effects is predicted [165,166].

8. Practice points

- Multiple pharmacokinetic and pharmacodynamic interactions with food, herbs, over-the-counter and other drugs can influence efficacy and safety of both vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).
- Bleeding disorders associated to VKAs-interactions have been often described as severe, life-threatening and even fatal, whereas those associated to DOACs-interactions appear to be less relevant.
- VKAs interactions have been widely investigated; those involving DOACs were much less studied.

Research agenda

The safety profile of DOACs with a specific focus on their interactions with foods, herbs and/or over-the-counter medications needs further assessments.

Conflict of interest

None.

Funding

This study was supported by the Italian Ministry of Health (Ministero Della Salute; Ricerca Corrente).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.blre.2017.02.001>.

References

- [1] Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141(Suppl. 2):e44S–88S.
- [2] Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. *Gastrointest Endosc* 2003;58(3):369–73.
- [3] Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet* 2010;376(9745):975–83.
- [4] De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. *J Am Coll Cardiol* 2012;59(16):1413–25.
- [5] Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. *Cardiol Clin* 2008;26(2):157–67 v.
- [6] Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. *Am J Med* 2006;119(7):607–15.
- [7] Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, et al. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med* 2013;8(6):509–20.
- [8] Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. *BMJ* 2006;333(7571):726.
- [9] Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med* 2010;170(16):1433–41.
- [10] Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. *Drug Metab Rev* 2003;35(1):35–98.
- [11] Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci* 2002;71(13):1579–89.
- [12] Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. *Thromb Haemost* 2014;111(5):798–807.
- [13] American College of Cardiology F, American Heart A, European Society of C, Heart Rhythm S, Wann LS, Curtis AB, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation* 2013;127(18):1916–26.
- [14] Di Minno A, Spadarella G, Prisco D, Scalera A, Ricciardi E, Di Minno G. Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: clinical translation and areas of research. *Blood Rev* 2015;29(5):335–43.
- [15] Di Minno G, Ricciardi E, Scalera A. Laboratory tests during direct oral anticoagulant treatment? *No Intern Emerg Med* 2013;8(5):367–70.
- [16] Harder S, Thurmman P. Clinically important drug interactions with anticoagulants. An update. *Clin Pharmacokinet* 1996;30(6):416–44.
- [17] Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133(Suppl. 6):160S–98S.
- [18] Bungard TJ, Schindel TJ, Garg S, Brocklebank C. Evaluation of a multi staged professional development course for practising pharmacists in anticoagulation management. *Int J Pharm Pract* 2012;20(2):107–17.
- [19] Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. *Am J Cardiovasc Drugs* 2014;14(3):175–89.
- [20] Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. *Expert Opin Drug Saf* 2006;5(3):433–51.
- [21] Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. *Clin Pharmacol Ther* 2002;71(3):115–21.
- [22] Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. *J Clin Pharmacol* 2005;45(2):127–32.
- [23] Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. *Clin Geriatr Med* 2006;22(1):17–32 (vii–viii).
- [24] Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med* 2005; 165(10):1095–106.

- [25] Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. *Ann Pharmacother* 2007;41(7):1292–5.
- [26] Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. *Pharmacotherapy* 2004;24(2):285–90.
- [27] Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. *J Clin Pharmacol* 1999;39(1):86–90.
- [28] Nutescu E, Chuatrismón I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. *J Thromb Thrombolysis* 2011;31(3):326–43.
- [29] Lambert CT, Sandesara PB, Hirsh B, Shaw LJ, Lewis W, Quyyumi AA, et al. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. *HIV Med* 2016;17(6):411–24.
- [30] Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. *Expert Opin Drug Saf* 2010;9(2):215–23.
- [31] Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. *Ann Pharmacother* 2009;43(2):322–8.
- [32] Bonora S, Lanzafame M, D'Avolio A, Trentini L, Lattuada E, Concia E, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. *Clin Infect Dis* 2008;46(1):146–7.
- [33] Dionisio D, Mininni S, Bartolozzi D, Esperti F, Vivarelli A, Leoncini F. Need for increased dose of warfarin in HIV patients taking nevirapine. *AIDS* 2001;15(2):277–8.
- [34] Mathews S, Cole J, Ryoona RA. Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. *Pharmacotherapy* 2006;26(10):1446–52.
- [35] Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. *Am J Geriatr Pharmacother* 2003;1(2):53–60.
- [36] Miki A, Ohtani H, Sawada Y. Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. *J Clin Pharm Ther* 2011;36(6):642–50.
- [37] Kassebaum PJ, Shaw DL, Tomich DJ. Possible warfarin interaction with menthol cough drops. *Ann Pharmacother* 2005;39(2):365–7.
- [38] Coderre K, Faria C, Dyer E. Probable warfarin interaction with menthol cough drops. *Pharmacotherapy* 2010;30(1):110.
- [39] Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(Suppl. 2):e152S–84S.
- [40] Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. *Am J Cardiol* 2012;110(3):453–60.
- [41] Howard PA, Ellerbeck EF, Engelmann KJ, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. *Pharmacoevidentiol Drug Saf* 2002;11(7):569–76.
- [42] Tadros R, Shakib S. Warfarin-indications, risks and drug interactions. *Aust Fam Physician* 2010;39(7):476–9.
- [43] Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. *Blood* 2011;118(24):6269–73.
- [44] van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. *BMJ* 2009;339:b2921.
- [45] Franchi F, Biguzzi E, Martinelli I, Bucciarelli P, Palmucci C, D'Agostino S, et al. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. *Thromb Res* 2013;132(2):e152–7.
- [46] Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. *Ann Pharmacother* 2007;41(10):1617–24.
- [47] Smith L, Ernst E, Ewings Paul, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. *Br J Gen Pract* 2004;54(503):439–41.
- [48] Chan HT, So LT, Li SW, Liu CP, Tse HF. Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. *J Cardiovasc Pharmacol* 2011;58(1):87–90.
- [49] Qiu JX, Zhou ZW, He ZX, Zhang X, Zhou SF, Zhu S. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. *Drug Des Devel Ther* 2015;9:841–66.
- [50] Schmidt LE, Dalhoff K. Food-drug interactions. *Drugs* 2002;62(10):1481–502.
- [51] Nowack R, Andrassy J, Fischer M, Unger M. Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients. *Clin Pharmacol Ther* 2009;85(4):439–43.
- [52] Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. *Br J Clin Pharmacol* 2010;70(2):164–70.
- [53] Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. *Acta Pharmacol Sin* 2004;25(2):129–36.
- [54] Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. *Evid Based Complement Alternat Med* 2014;2014:957362.
- [55] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G. Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy. *Eur J Clin Pharmacol* 2007;63(6):565–70.
- [56] Cheng TO. Green tea may inhibit warfarin. *Int J Cardiol* 2007;115(2):236.
- [57] Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phyloquinone). *J Am Diet Assoc* 1995;95(1):82–3.
- [58] Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. *Integr Cancer Ther* 2009;8(3):208–27.
- [59] Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs* 2009;69(13):1777–98.
- [60] Ganzer M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (*Matricaria recutita* L.) and its major constituents on human cytochrome P450 enzymes. *Life Sci* 2006;78(8):856–61.
- [61] Rodríguez-Fragoso L, Reyes-Esparza J, Burchiel SW, Herrera-Ruiz D, Torres E. Risks and benefits of commonly used herbal medicines in Mexico. *Toxicol Appl Pharmacol* 2008;227(1):125–35.
- [62] Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. *J Natl Cancer Inst* 2006;98(7):459–71.
- [63] Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. *Blood* 2004;104(9):2682–9.
- [64] Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. *Ann Pharmacother* 2002;36(12):1893–6.
- [65] Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. *Phytomedicine* 2003;10(4):334–42.
- [66] Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. *Int J Cardiol* 2005;98(1):1–14.
- [67] Monterrey-Rodríguez J. Interaction between warfarin and mango fruit. *Ann Pharmacother* 2002;36(5):940–1.
- [68] Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004;57(5):592–9.
- [69] McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. *Semin Thromb Hemost* 2015;41(3):300–14.
- [70] Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, et al. *Hypericum perforatum*: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. *Phytother Res* 2014;28(5):643–55.
- [71] Dostalek M, Pistovcakova J, Jurica J, Sulcova A, Tomandl J. The effect of St John's wort (*hypericum perforatum*) on cytochrome P450 1a2 activity in perfused rat liver. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2011;155(3):253–7.
- [72] Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. *J Pharmacol Exp Ther* 2004;308(2):495–501.
- [73] Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. *Xenobiotica* 2002;32(6):451–78.
- [74] Sprouse AA, van Breemen RB. Pharmacokinetic interactions between drugs and botanical dietary supplements. *Drug Metab Dispos* 2016;44(2):162–71.
- [75] von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Hartzel JS, Goldman P, et al. Inhibition of human cytochromes P450 by components of *Ginkgo biloba*. *J Pharm Pharmacol* 2004;56(8):1039–44.
- [76] Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and *Ginkgo biloba* on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. *Thromb Haemost* 2002;87(6):1075–6.
- [77] Suvama R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. *BMJ* 2003;327(7429):1454.
- [78] Griffiths AP, Beddall A, Pegler S. Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin. *J R Soc Promot Heal* 2008;128(6):324–6.
- [79] Hamann GL, Campbell JD, George CM. Warfarin-cranberry juice interaction. *Ann Pharmacother* 2011;45(3):e17.
- [80] Dismore ML, Haytowitz DB, Gebhardt SE, Peterson JW, Booth SL. Vitamin K content of nuts and fruits in the US diet. *J Am Diet Assoc* 2003;103(12):1650–2.
- [81] Haber SL, Cauthon KA, Raney EC. Cranberry and warfarin interaction: a case report and review of the literature. *Consult Pharm* 2012;27(1):58–65.
- [82] Srinivas NR. Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. *J Pharm Pharm Sci* 2013;16(2):289–303.
- [83] Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Hartzel JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. *Clin Pharmacol Ther* 2006;79(1):125–33.
- [84] Li Z, Seeram NP, Carpenter CL, Thames G, Minutti C, Bowerman S. Cranberry does not affect prothrombin time in male subjects on warfarin. *J Am Diet Assoc* 2006;106(12):2057–61.
- [85] Ansell J, McDonough M, Zhao Y, Hartzel JS, Greenblatt DJ. The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. *J Clin Pharmacol* 2009;49(7):824–30.
- [86] Mellen CK, Ford M, Rindone JP. Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. *Br J Clin Pharmacol* 2010;70(1):139–42.
- [87] Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. *Lancet* 1987;1(8527):248–51.
- [88] Matthews Jr MK. Association of *Ginkgo biloba* with intracerebral hemorrhage. *Neurology* 1998;50(6):1933–4.
- [89] Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2005;59(4):425–32.
- [90] Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. *Ann Intern Med* 2004;141(1):23–7.
- [91] Summaries for patients Ginseng reduces the effect of warfarin in a study of healthy volunteers. *Ann Intern Med* 2004;141(1):158.
- [92] Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. *Am J Health Syst Pharm* 1997;54(6):692–3.
- [93] Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. *Cardiology* 2003;99(2):111.
- [94] Schlienger R, Kurmann M, Drewe J, Muller-Spahn F, Seifritz E. Inhibition of phenprocoumon anticoagulation by carbamazepine. *Eur Neuropsychopharmacol* 2000;10(3):219–21.
- [95] Sommer N, Grimminger J, Ghofrani HA, Tiede H. Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. *Pulm Pharmacol Ther* 2014;28(1):87–9.
- [96] Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. *Eur J Clin Pharmacol* 2015;71(12):1461–5.

- [97] Wijnen JC, van de Riet IR, Lijfering WM, van der Meer FJ. Metformin use decreases the anticoagulant effect of phenprocoumon. *J Thromb Haemost* 2014;12(6):887–90.
- [98] Meyboom RH, Heere FJ, Egberts AC, Lastdrager CJ. Possible potentiation of phenprocoumon by clarithromycin and roxithromycin. *Ned Tijdschr Geneesk* 1996;140(7):375–7.
- [99] Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. *J Clin Psychiatry* 2010;71(12):1565–75.
- [100] Schalekamp T, van Geest-Daelderop JH, Kramer MH, van Holten-Verzantvoort AT, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. *Eur J Clin Pharmacol* 2007;63(4):335–43.
- [101] Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. *Eur J Clin Pharmacol* 2011;67(9):941–51.
- [102] Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. *Clin Pharmacol Ther* 2008;84(5):581–8.
- [103] Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. *Ann Pharmacother* 2003;37(3):367–70.
- [104] Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. *Arch Intern Med* 2008;168(2):180–5.
- [105] Bousquet P. Pharmacology of neurotransmitters. Current data on the central regulation of blood pressure. *Therapie* 1990;45(Suppl. 2):171–5.
- [106] Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Grunenwald M, et al. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. *Pharmacogenomics* 2013;14(7):745–53.
- [107] Palacios-Zabalza I, Bustos-Martinez M, Peral-Aguirregotia J, Martinez-Bengochea MJ, Aguirre Gomez C. Probable interaction between acenocoumarol and levofloxacin: a case series. *J Clin Pharm Ther* 2015;40(6):693–5.
- [108] Morales-Molina JA, Arrebola MA, Robles PA, Mangana JC. Possible interaction between topical terbinafine and acenocoumarol. *Ann Pharmacother* 2009;43(11):1911–2.
- [109] Morales-Molina JA, Fayet-Perez A, Martinez-Plata E, Perez-Moyano R, Molina-Arrebola MA. Interaction between amorfoline and acenocoumarol. *Eur J Clin Pharmacol* 2012;68(12):1687–8.
- [110] Morales-Molina JA, Perez-Moyano R, Fayet-Perez A, Urquizar-Rodriguez O, Gimenez-Lopez MJ. Interaction between ciclopirox and acenocoumarol. *Eur J Clin Pharmacol* 2013;69(3):727–8.
- [111] Ribed A, Escudero-Vilaplana V, Gonzalez-Haba E, Sanjurjo M. Increased INR after gefitinib and acenocoumarol co-administration. *Eur Rev Med Pharmacol Sci* 2014;18(12):1720–2.
- [112] Tomlow B, Voll ML, Smorenburg CH. Increased INR from concomitant use of acenocoumarol and capcatabine. *Ned Tijdschr Geneesk* 2012;156(26):A4793.
- [113] Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. *J Assoc Physicians India* 2008;56:250–2.
- [114] Welzen ME, van den Berk GE, Hamers RL, Burger DM. Interaction between antiretroviral drugs and acenocoumarol. *Antivir Ther* 2011;16(2):249–52.
- [115] Morales-Molina JA, Martinez-de la Plata JE, Urquizar-Rodriguez O, Molina-Arrebola MA. Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far. *Hematol Rep* 2011;3(2):e16.
- [116] Pulido T, Sandoval J, Roquet I, Gutierrez R, Rueda T, Pena H, et al. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. *Eur J Clin Investig* 2009;39(Suppl. 2):14–8.
- [117] Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. *Br J Haematol* 2011;153(3):379–85.
- [118] Wey PF, Petitjeans F, Lions C, Ould-Ahmed M, Escarment J. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. *Am J Geriatr Pharmacother* 2008;6(3):173–7.
- [119] Paoletti A, Gallo E, Benemei S, Vietri M, Lapi F, Volpi R, et al. Interactions between natural health products and oral anticoagulants: spontaneous reports in the Italian Surveillance System of Natural Health Products. *Evid Based Complement Alternat Med* 2011;2011:612150.
- [120] Delavenne X, Laporte S, Demasles S, Mallouk N, Basset T, Tod M, et al. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. *Fundam Clin Pharmacol* 2009;23(1):127–35.
- [121] Oertle M. Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. *Swiss Med Wkly* 2012;142:w13522.
- [122] Blech S, Ebner T, Ludwig-Schwelliger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. *Drug Metab Dispos* 2008;36(2):386–99.
- [123] Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. *Clin Pharmacokinet* 2013;52(2):69–82.
- [124] Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. *Int J Clin Pract* 2010;64(7):956–67.
- [125] Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. *Clin Pharmacokinet* 2009;48(1):1–22.
- [126] Eisert WG, Haul N, Stangier J, Wiene W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. *Arterioscler Thromb Vasc Biol* 2010;30(10):1885–9.
- [127] Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(R)) after co-medication with verapamil in healthy subjects. *Br J Clin Pharmacol* 2013;75(4):1053–62.
- [128] Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. *Semin Thromb Hemost* 2013;39(7):840–6.
- [129] Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. *J Clin Pharmacol* 2005;45(5):555–63.
- [130] Seiffge D, Nedeltchev K, Lyrrer P. The new anticoagulants - their role in secondary prevention of thromboembolism after stroke. *Ther Umsch* 2012;69(9):517–22.
- [131] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361(12):1139–51.
- [132] Chin PK, Barclay ML, Begg EJ. Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. *Br J Clin Pharmacol* 2013;75(2):554–5.
- [133] Gnath MJ, Buethorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. *J Pharmacol Exp Ther* 2011;338(1):372–80.
- [134] Kubitzka D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. *Br J Clin Pharmacol* 2013;76(1):89–98.
- [135] Rathbone RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. *Pharmaceutics* 2011;3(4):745–81.
- [136] Kubitzka D, Becka M, Mueck W, Zuehlendorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. *J Clin Pharmacol* 2006;46(9):981–90.
- [137] Mueck W, Stampfuss J, Kubitzka D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. *Clin Pharmacokinet* 2014;53(1):1–16.
- [138] Kubitzka D, Becka M, Mueck W, Schwes S. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. *Pharmaceuticals (Basel)* 2012;5(3):279–96.
- [139] Kubitzka D, Becka M, Mueck W, Zuehlendorf M. Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen. *Br J Clin Pharmacol* 2007;63(4):469–76.
- [140] Di Minno A, Spadarella G, Spadarella E, Tremoli E, Di Minno G. Gastrointestinal bleeding in patients receiving oral anticoagulation: current treatment and pharmacological perspectives. *Thromb Res* 2015;136(6):1074–81.
- [141] Lippi G, Favoloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? *Semin Thromb Hemost* 2014;40(7):756–65.
- [142] Cabral KP. Pharmacology of the new target-specific oral anticoagulants. *J Thromb Thrombolysis* 2013;36(2):133–40.
- [143] Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. *Drug Metab Dispos* 2010;38(3):448–58.
- [144] Carreiro J, Ansell J. Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. *Expert Opin Investig Drugs* 2008;17(12):1937–45.
- [145] Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. *Ann Pharmacother* 2011;45(10):1262–83.
- [146] Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. *Br J Clin Pharmacol* 2013;75(2):476–87.
- [147] Committee AS, Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation* 2009;119(22):2877–85.
- [148] Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. *Br J Clin Pharmacol* 2014;78(4):877–85.
- [149] Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. *Drugs* 2014;74(11):1209–31.
- [150] Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. *Am J Cardiovasc Drugs* 2013;13(5):331–42.
- [151] Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor xA next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). *Am Heart J* 2010;160(4):635–41.
- [152] Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, bio-transformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. *Drug Metab Dispos* 2012;40(12):2250–5.
- [153] Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. *Thromb J* 2014;12:22.
- [154] Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. *Br J Clin Pharmacol* 2013;75(4):966–78.
- [155] Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. *J Cardiovasc Pharmacol* 2013;62(2):212–21.
- [156] Stollberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. *Herz* 2015;40(Suppl. 2):140–5.
- [157] Wilkinson GR. Drug metabolism and variability among patients in drug response. *N Engl J Med* 2005;352(21):2211–21.
- [158] Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. *Clin Pharmacokinet* 2008;47(9):565–94.
- [159] Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. *Clin Pharmacol Ther* 2004;75(5):376–80.
- [160] Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. *Clin Pharmacol Ther* 2004;75(3):198–203.
- [161] Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. *Br J Haematol* 2004;124(3):348–54.
- [162] Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. *Eur J Clin Pharmacol* 2007;63(12):1135–41.

- [163] Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. *Pharmacogenomics* 2007;8(11):1535–44.
- [164] Gericke KR. Possible interaction between warfarin and fluconazole. *Pharmacotherapy* 1993;13(5):508–9.
- [165] Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015;131(2):157–64.
- [166] Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. *Thromb Haemost* 2015;113(6):1247–57.
- [167] Weinz C, Schwarz T, Kubitzka D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. *Drug Metab Dispos* 2009;37(5):1056–64.
- [168] Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. *Eur J Clin Pharmacol* 2013;69(9):1617–33.
- [169] Klausner W, Dutsch M. Practical management of new oral anticoagulants after total hip or total knee arthroplasty. *Musculoskelet Surg* 2013;97(3):189–97.
- [170] Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. *Epileptic Disord* 2014;16(4):409–31.
- [171] Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. *J Cardiovasc Pharmacol Ther* 2010;15(Suppl. 4):155–85.
- [172] Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A. CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. *Tissue Antigens* 1999;53(3):296–300.
- [173] Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. *Drug Saf* 2000;23(6):509–32.
- [174] Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994;121(9):676–83.
- [175] Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, et al. Identification of CYP3A4 as the enzyme involved in the mono-*N*-dealkylation of disopyramide enantiomers in humans. *Drug Metab Dispos* 2000;28(8):937–44.
- [176] He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. *Clin Pharmacokinet* 2012;51(3):147–62.
- [177] Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in *N*-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. *Mol Pharmacol* 1993;43(1):120–6.
- [178] Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. *Drug Metab Dispos* 2003;31(11):1352–60.
- [179] Barry M. Rosuvastatin-warfarin drug interaction. *Lancet* 2004;363(9405):328.
- [180] Stangier J, Su CA, Hendriks MG, van Lier JJ, Sollié FA, Oosterhuis B, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. *J Clin Pharmacol* 2000;40(12 Pt 1):1331–7.
- [181] Ghaswalla PK, Harpe SE, Tassone D, Slattum PW. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic. *Am J Geriatr Pharmacother* 2012;10(6):352–60.
- [182] Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. *Pharmacotherapy* 1999;19(7):902–8.
- [183] Bint AJ, Burt I. Adverse antibiotic drug interactions. *Drugs* 1980;20(1):57–68.
- [184] Washington C, Hou SY, Hughes NC, Campanella C, Berner B. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. *J Clin Pharmacol* 2007;47(10):1320–6.
- [185] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. *Arch Intern Med* 2010;170(7):617–21.
- [186] Hasan SA. Interaction of doxycycline and warfarin: an enhanced anticoagulant effect. *Cornea* 2007;26(6):742–3.
- [187] Haas S, Bode C, Norrving B, Turpie AG. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. *Vasc Health Risk Manag* 2014;10:101–14.
- [188] Seaton TL, Celum CL, Black DJ. Possible potentiation of warfarin by fluconazole. *DICP* 1990;24(12):1177–8.
- [189] Mercadal Orfila G, Gracia Garcia B, Leiva Badosa E, Perayre Badia M, Reynaldo Martinez C, Jodar Masanes R. Retrospective assessment of potential interaction between levofloxacin and warfarin. *Pharm World Sci* 2009;31(2):224–9.
- [190] Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. *Am J Geriatr Pharmacother* 2008;6(1):33–6.
- [191] Silingardi M, Ghirarduzzi A, Tincani E, Iorio A, Iori I. Miconazole oral gel potentiates warfarin anticoagulant activity. *Thromb Haemost* 2000;83(5):794–5.
- [192] Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. *Pharmacotherapy* 2000;20(1):98–9.
- [193] Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. *Ann Pharmacother* 2014;48(6):734–40.
- [194] Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. *Ann Pharmacother* 1997;31(5):647.
- [195] Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. *Br J Clin Pharmacol* 2003;56(Suppl. 1):24–9.
- [196] Matsumura Y, Yokota M, Yoshioka H, Shibata S, Ida S, Takiguchi Y. Acute effects of griseofulvin on the pharmacokinetics and pharmacodynamics of warfarin in rats. *J Int Med Res* 1999;27(4):167–75.
- [197] Kim KY, Frey RJ, Eppelen K, Foruhari F. Interaction between warfarin and nafcillin: case report and review of the literature. *Pharmacotherapy* 2007;27(10):1467–70.
- [198] Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, et al. Effects of *Ginkgo biloba* extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. *Ann Pharmacother* 2009;43(5):944–9.
- [199] Colombo D, Lunardon L, Bellia G. Cyclosporine and herbal supplement interactions. *J Toxicol* 2014;2014:145325.
- [200] Jin MJ, Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. *J Food Sci* 2010;75(3):H93–6.
- [201] Ahmed IS, Hassan MA, Kondo T. Effect of lyophilized grapefruit juice on P-glycoprotein-mediated drug transport in-vitro and in-vivo. *Drug Dev Ind Pharm* 2015;41(3):375–81.
- [202] Kumar KK, Priyanka L, Gnananath K, Babu PR, Sujatha S. Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats. *Eur J Drug Metab Pharmacokinet* 2015;40(3):267–76.
- [203] Yu CP, Hsieh YW, Lin SP, Chi YC, Hariharan P, Chao PD, et al. Potential modulation on P-glycoprotein and CYP3A by soy milk and miso: in vivo and ex-vivo studies. *Food Chem* 2014;149:25–30.
- [204] Schiffman SS, Rother KI. Sucralose, a synthetic organochlorine sweetener: overview of biological issues. *J Toxicol Environ Health B Crit Rev* 2013;16(7):399–451.
- [205] Zhai XJ, Shi F, Chen F, Lu YN. Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition. *Food Chem Toxicol* 2013;62:323–8.
- [206] El-Readi MZ, Hamdan D, Farrag N, El-Shazly A, Wink M. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from *Citrus* species in human colon and leukaemia cell lines. *Eur J Pharmacol* 2010;626(2–3):139–45.
- [207] Gao LN, Zhang Y, Cui YL, Yan K. Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro. *Fitoterapia* 2014;98:130–6.
- [208] Bogacz A, Bartkowiak-Wieczorek J, Mikolajczak PL, Rakowska-Mrozikiewicz B, Grzeskowiak E, Wolski H, et al. The influence of soybean extract on the expression level of selected drug transporters, transcription factors and cytochrome P450 genes encoding phase I drug-metabolizing enzymes. *Ginekol Pol* 2014;85(5):348–53.
- [209] Chieli E, Romiti N, Rodeiro I, Garrido G. In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from *Mangifera indica*. *Chem Biol Interact* 2010;186(3):287–94.
- [210] Chula S, Hang L, Yinying B, Jianning S, Shi R. The effects of notoginsenoside R(1) on the intestinal absorption of geniposide by the everted rat gut sac model. *J Ethnopharmacol* 2012;142(1):136–43.
- [211] Si M, Zhao J, Li X, Tian JG, Li YG, Li JM. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. *Chin Med J* 2013;126(21):4116–23.
- [212] Mei Y, Qian F, Wei D, Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. *J Pharm Pharmacol* 2004;56(10):1307–14.
- [213] Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. *J Biol Regul Homeost Agents* 2010;24(2):197–205.